Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia
NCT05829460
Recruiting
The investigators hypothesize that combined treatment with the GLP-1R agonist semaglutide 2.4 mg and levonorgestrel intrauterine device (LNG-IUD), compared to LNG-IUD alone, will result in improved likelihood of uterine preservation, sustained weight loss, improved endometrial and metabolomic response to progestin, and improved quality of life in premenopausal women with endometrial hyperplasia who desire uterine preservation.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
08/18/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Endometrial Hyperplasia
Register for Updates
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
NCT03884075
Recruiting
Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help. Objective: To find out how the liver in people with NAFLD responds to feeding, and how this relates to their response to the drug semaglutide. Eligibility: People with NAFLD and healthy volunteers ages 18 and older Design: Participants will be screened with: Medical history Physical exam... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/16/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
Register for Updates
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
NCT07112872
Recruiting
This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Emerson Clinical Research Institute, Washington, District of Columbia +5 locations
Conditions: Type 2 Diabetes Mellitus
Register for Updates
GLP-1R Agonist Treatment for Opioid Use Disorder
NCT06548490
Recruiting
The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is: • Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids? The investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semagl... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/11/2025
Locations: University of Maryland Baltimore, Baltimore, Maryland +2 locations
Conditions: Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
Register for Updates
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
NCT03811561
Active Not Recruiting
This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: Del Sol Research Management, LLC, Tucson, Arizona +182 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
NCT04865770
Completed
We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys. Participants will either get semaglutide or placebo (a 'dummy' medicine) - which treatment participants get is decided by chance. Semaglutide is a medicine doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: Academic Medical Research Institute, Los Angeles, California +30 locations
Conditions: Diabetes Mellitus, Type 2, Chronic Kidney Disease
Register for Updates
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
NCT05514535
Completed
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home vi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: San Fernando Valley Hlth Inst, LLC, Canoga Park, California +112 locations
Conditions: Diabetes Mellitus, Type 2, Obesity
Register for Updates
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06717698
Recruiting
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a "dummy" substance). Which treatment the participant will get is decided by chance. The study wil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: N America Res Inst - San Dimas, San Dimas, California +128 locations
Conditions: Chronic Kidney Disease
Register for Updates
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
NCT04916470
Completed
This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight. This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart failure symptoms. Participants will either get semaglutide or "dummy" medicine, which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: Eastern Shore Rsrch Inst, LLC, Fairhope, Alabama +120 locations
Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Register for Updates
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
NCT04596631
Active Not Recruiting
This study compares 2 medicines for type 2 diabetes: semaglutide (new medicine) and a dummy medicine (placebo). Semaglutide will be tested to see how well it works compared to the dummy medicine. The study will also test if semaglutide is safe in children and teenagers. Participants will either get semaglutide or the dummy medicine - which one is decided by chance. Participants will take 1 tablet of the study medicine every morning on an empty stomach. They have to wait 30 minutes before they ea... Read More
Gender:
ALL
Ages:
Between 10 years and 18 years
Trial Updated:
08/10/2025
Locations: Children's Hospital Los Angeles - Endocrinology, Los Angeles, California +63 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06571383
Recruiting
The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.
Gender:
ALL
Ages:
Between 12 years and 15 years
Trial Updated:
08/08/2025
Locations: Neighborhood Healthcare, Escondido, California +100 locations
Conditions: Obesity
Register for Updates
Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims
NCT06659744
Completed
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/04/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
Register for Updates